EUVIMEDEUVIMED entdecken
Crossref

Real-World Clinical Characteristics and Treatment Patterns of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: A Nationwide Korean EGFR Registry

Myeong Geun Choi, Chang Dong Yeo, Seong Hoon Yoon, Eun Young Kim, Jeong Eun Lee, Shin Yup Lee, In-Jae Oh, Do Jin Kim, Jeong Seon Ryu, Jae Cheol Lee, Young-Chul Kim, Tae Won Jang und 6 weitere

Cancer Research and Treatment · 18.11.2026

DOI: 10.4143/crt.2026.0847 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, online erschienen am 18.11.2026. Verfasst von Myeong Geun Choi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Despite advances in epidermal growth factor receptor (EGFR)-targeted therapy for non-small cell lung cancer (NSCLC), real-world data on diagnostic and treatment patterns across all disease stages remain limited. This study used the nationwide Korean EGFR Registry to characterize contemporary clinical practice in EGFR-mutant NSCLC. Materials and Methods A total of 1,522 patients with pathologically confirmed EGFR-mutant NSCLC were prospectively enrolled from 40 Korean institutions (June 2022–June 2024). Data on baseline clinical and molecular characteristics, biomarker testing patterns, and treatment for all lines of therapy were collected using standardized electronic case report forms.

Results

The median age of the study population was 68 years, 59.7% were female, and 64.5% were never-smokers. Stage IV disease accounted for 57.8% of cases. The predominant EGFR mutations were exon 19 deletion (48.6%) and L858R (47.1%). NGS was performed for ~23% of patients. In patients with stage IV disease, third-generation TKI use increased markedly (14.3% in 2022 vs. 91.1% in 2024). Stage III management was notably heterogeneous; definitive concurrent chemoradiotherapy was used in only 15.3% of stage III patients overall, with surgery-based treatment predominating in stage IIIA and systemic therapy accounting for all treatment in stage IIIC. The 3-year overall survival rates were 97.2%, 90.9%, 78.3%, and 58.4% for stages I–IV, respectively.

Conclusion

This nationwide registry analysis reveals rapid adoption of third-generation TKIs in metastatic EGFR-mutant NSCLC and substantial heterogeneity in stage III disease management. These findings provide clinically meaningful insights into the evolving treatment paradigm of EGFR-mutant NSCLC across disease stages in routine practice.

Schlagwörter

Stichwörter der Autor:innen

Epidermal growth factor receptor mutationNon-small cell lung cancerProspective registry study

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, Catholic University of Korea, Seoul, Korea.
  • Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea.
  • Division of Pulmonology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • Division of Pulmonology, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Korea.
  • Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.

Zitieren

APA

Choi, M. G., Yeo, C. D., Yoon, S. H., Kim, E. Y., Lee, J. E., Lee, S. Y., Oh, I. J., Kim, D. J., Ryu, J. S., Lee, J. C., Kim, Y. C., Jang, T. W., Lee, K. Y., Lee, S. Y., Park, C. K., Jang, S. H., Kim, S. J., & Korean EGFR Registry Investigators (2026). Real-World Clinical Characteristics and Treatment Patterns of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: A Nationwide Korean EGFR Registry. Cancer Research and Treatment. https://doi.org/10.4143/crt.2026.0847

Vancouver

Choi MG, Yeo CD, Yoon SH, Kim EY, Lee JE, Lee SY, et al. Real-World Clinical Characteristics and Treatment Patterns of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: A Nationwide Korean EGFR Registry. Cancer Research and Treatment. 2026. doi:10.4143/crt.2026.0847

BibTeX
@article{Choi2026,
  author = {Choi, Myeong Geun and Yeo, Chang Dong and Yoon, Seong Hoon and Kim, Eun Young and Lee, Jeong Eun and Lee, Shin Yup and Oh, In-Jae and Kim, Do Jin and Ryu, Jeong Seon and Lee, Jae Cheol and Kim, Young-Chul and Jang, Tae Won and Lee, Kye Young and Lee, Sung Yong and Park, Cheol-Kyu and Jang, Seung Hun and Kim, Seung Joon and Korean EGFR Registry Investigators, Korean EGFR Registry Investigators},
  title = {Real-World Clinical Characteristics and Treatment Patterns of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: A Nationwide Korean EGFR Registry},
  journal = {Cancer Research and Treatment},
  year = {2026},
  doi = {10.4143/crt.2026.0847}
}
Kostenlos starten →